Late SV40 factor: A key mediator of Notch signaling in human hepatocarcinogenesis

被引:61
作者
Fan, Ren-Hua [1 ]
Li, Jing [1 ]
Wu, Nan [1 ]
Chen, Ping-Sheng [1 ]
机构
[1] Southeast Univ, Dept Pathol, Sch Med, Nanjing 210009, Jiangsu Prov, Peoples R China
基金
中国国家自然科学基金;
关键词
Notch receptor; Late SV40 factor; Signal transduction; Hepatocellular carcinoma; TRANSCRIPTION FACTOR LSF; HEPATOCELLULAR-CARCINOMA; MITOGENIC STIMULATION; GROWTH; INHIBITION; CANCER; PHOSPHORYLATION; ACTIVATION; EXPRESSION; SURVIVAL;
D O I
10.3748/wjg.v17.i29.3420
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
AIM: To investigate the relationship between late SV40 factor (LSF) and Notch signaling in the development and progress of hepatocellular carcinoma (HCC). METHODS: Liver cancer tissue specimens from 25 patients were analyzed for Notch-1 and LSF expression by immunohistochemistry. The correlation between expression and the biological effects of Notch-1 and LSF were analyzed using genetic and pharmacological strategies in HCC cell lines and human normal cell lines, including hepatic stellate cells (HSC) and human embryonic kidney epithelial cells (HEK). RESULTS: Immunohistochemistry showed that both Notch-1 and LSF were significantly upregulated in HCC samples (76%, 19/25, P < 0.0001 and 84%, 21/25, P < 0.0001, respectively) compared with non-cancer samples. Activation of Notch-1 by exogenous transfection of Notch1 intracellular domain increased LSF expression in HSC and HEK cells to levels similar to those seen in HepG2 cells. Furthermore, blocking Notch-1 activation with a gamma-secretase inhibitor, DAPT, downregulated LSF expression in HepG2 cells. Additionally, a biological behavior assay showed that forced overexpression of LSF promoted HepG2 cell proliferation and invasion. CONCLUSION: LSF is a key mediator of the Notch signaling pathway, suggesting that it might be a novel therapeutic target for the treatment of HCC. (C) 2011 Baishideng. All rights reserved.
引用
收藏
页码:3420 / 3430
页数:11
相关论文
共 36 条
[1]
The link between integration and expression of human papillomavirus type 16 genomes and cellular changes in the evolution of cervical intraepithelial neoplastic lesions [J].
Daniel, B ;
Rangarajan, A ;
Mukherjee, G ;
Vallikad, E ;
Krishna, S .
JOURNAL OF GENERAL VIROLOGY, 1997, 78 :1095-1101
[2]
Prognostic Impact of Notch Ligands and Receptors in Nonsmall Cell Lung Cancer Coexpression of Notch-1 and Vascular Endothelial Growth Factor-A Predicts Poor Survival [J].
Donnem, Tom ;
Andersen, Sigve ;
Al-Shibli, Khalid ;
Al-Saad, Samer ;
Busund, Lill-Tove ;
Bremnes, Roy M. .
CANCER, 2010, 116 (24) :5676-5685
[3]
EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO
[4]
2-E
[5]
Ferenci P, 2010, J GASTROINTEST LIVER, V19, P311
[6]
RUNX3 directly interacts with intracellular domain of Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells [J].
Gao, Juan ;
Chen, Yu ;
Wu, Kai-Chun ;
Liu, Jie ;
Zhao, Yan-Qiu ;
Pan, Yang-Lin ;
Du, Rui ;
Zheng, Guo-Rong ;
Xiong, Yi-Min ;
Xu, Hua-Lin ;
Fan, Dai-Ming .
EXPERIMENTAL CELL RESEARCH, 2010, 316 (02) :149-157
[7]
Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism [J].
Giovannini, Catia ;
Gramantieri, Laura ;
Chieco, Pasquale ;
Minguzzi, Manuela ;
Lago, Federica ;
Pianetti, Simona ;
Ramazzotti, Eric ;
Marcu, Kenneth B. ;
Bolondi, Luigi .
JOURNAL OF HEPATOLOGY, 2009, 50 (05) :969-979
[8]
Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing nonsurgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre [J].
Grieco, A ;
Pompili, M ;
Caminiti, G ;
Miele, L ;
Covino, M ;
Alfei, B ;
Rapaccini, GL ;
Gasbarrini, G .
GUT, 2005, 54 (03) :411-418
[9]
Transcription factors LSF and E2Fs Tandem cyclists driving G0 to S? [J].
Hansen, Ulla ;
Owens, Laura ;
Saxena, Utsav H. .
CELL CYCLE, 2009, 8 (14) :2146-2151
[10]
Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma [J].
Jundt, F ;
Anagnostopoulos, I ;
Förster, R ;
Mathas, S ;
Stein, H ;
Dörken, B .
BLOOD, 2002, 99 (09) :3398-3403